INTRODUCTION
Human epidermal growth factor receptor 2 (HER2; HER2/neu or ERBB2) is a member of the HER family of receptor tyrosine kinases that includes HER1 (epidermal growth factor receptor [EGFR] or ERBB1), HER3, and HER4. 1 These receptors consist of a ligand-binding extracellular domain and an intracellular tyrosine kinase domain. The HER2 receptor does not have a known endogenous ligand for its extracellular domain. HER2 heterodimerizes with other HER family receptors and causes activation of downstream signaling through the PI3K/AKT and RAS/MAP/MEK pathways.
1 HER2 is a preferred dimerization partner of other HER receptors, and HER2-containing heterodimers can exert a potent oncogenic signal.
HER2 overexpression results in oncogenic transformation of cells, as demonstrated by cell culture 2 and transgenic mouse models. 3 The HER2 gene is amplified in approximately 15% to 20% of patients with breast cancers and is associated with aggressive disease behavior. 4, 5 The presence of HER2 amplification correlates with a shorter time to disease recurrence (P<.0001) and survival (P 5 .0011) in patients with lymph node-positive breast cancer. 5 In patients with lymph node-negative disease, overexpression of the HER2 protein also portends worse outcomes as an independent prognostic factor for decreased 10-year recurrence-free survival (odds ratio, 1.71; P 5 .01) and breast cancer-specific survival (odds ratio, 2.03; P 5 .003). 6 The development of monoclonal antibodies that target HER2 by binding to the extracellular domain, such as trastuzumab and pertuzumab, has resulted in prolonged progression-free survival and survival in patients with HER2-positive breast cancer, particularly when combined with chemotherapy. [7] [8] [9] [10] HER2 amplification also occurs in approximately 20% of patients with gastric and gastroesophageal junction cancers. 11 The addition of trastuzumab to chemotherapy in patients with HER2-overexpressing gastric or gastroesophageal junction tumors decreases the risk of death (hazard ratio, 0.74). 12 As in breast cancer, the presence of HER2 gene amplification predicts benefit from the use of trastuzumab.
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HER2 has been studied in patients with lung cancer for its potential role as a target for therapy. HER2 protein overexpression is observed in 6% to 30% of patients with lung cancers, [14] [15] [16] [17] and gene amplification is present in 2% to 20%. 15, 18, 19 Although these rates are similar to those in patients with breast and gastric cancers, clinical trials combining trastuzumab with chemotherapy, even selected by HER2 protein overexpression, have yielded disappointing results, 16, 17, 20 although there is a hint that patients with tumors with HER2 amplification may derive benefit. 19 The Cancer Genome Project published what to our knowledge is the first report of somatic mutations of HER2 in lung cancers in 2004. 19 Sequencing of HER2 in 120 lung tumors revealed somatic mutations in the kinase domain of the protein, in a similar position to that observed with the exon 20 insertion mutation in EGFR. 21 The prevalence of HER2 mutation in this series was 4% in lung cancers, with all mutations occurring in adenocarcinomas. Unlike patients with EGFR mutations, 4 of 5 patients with HER2 mutations were current or former smokers. The mutated tumors were not found to demonstrate HER2 protein overexpression by immunohistochemistry.
Further studies of HER2 mutations in patients with lung cancer have demonstrated its role as an oncogene. HER2 mutations in exon 20 cause constitutive activation and downstream signaling and can induce the development of lung tumors in mouse models. 22, 23 Cell line and mouse models of lung cancers with activating HER2 mutations can be treated successfully with dual EGFR/ HER2 inhibitors such as afatinib and or pan-HER inhibitors such as dacomitinib and neratinib. [23] [24] [25] [26] Other reports also have described the clinicopathologic features of HER2-mutated lung cancers. [27] [28] [29] [30] [31] [32] These 6 studies are summarized in Table 1. 27-32 HER2 mutations are found exclusively in patients with adenocarcinoma, and the incidence of the mutation is 0.84% to 2.6% in these cohorts. The majority of these mutations occur in exon 20, most commonly as a duplication or insertion coding for the amino acids YVMA at codon 776. Female patients and those who are never-smokers tend to harbor more HER2 mutations. Abbreviations: ALK, anaplastic lymphoma kinase; AKT, AKR mouse thymoma kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B1; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene; MEK1, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1; NR, not reported; NRAS, Neuroblastoma rat sarcoma viral oncogene; NSCLC, non-small cell lung cancer; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.
The Lung Cancer Mutation Consortium (LCMC) was developed as a collaboration between 14 academic centers in the United States to prospectively test specimens from patients with lung adenocarcinomas for 10 oncogenic drivers. 33 The ultimate goal, in addition to the feasibility of multiplexed testing, was to use these data in real time to guide therapeutic decisions using targeted therapies directed against these mutations. Greater than 1000 patients were tested prospectively in this effort. In the current study, we describe the analysis of HER2 mutations in the LCMC. This cohort is unique among prior reports regarding HER2 mutations in lung adenocarcinomas because it is limited to patients with an advanced stage of disease and includes treatment and survival outcomes.
MATERIALS AND METHODS
The LCMC enrolled patients from 14 sites who had metastatic or recurrent lung adenocarcinomas and a ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 2 and who provided written informed consent between 2009 and 2012. One specimen from each eligible patient was tested prospectively for specified mutations; pathologists at each site reviewed the diagnosis and adequacy of each tissue specimen. In addition, designated pathologists performed central confirmation of the diagnosis of adenocarcinoma. Demographic data including age, sex, smoking history, sites of metastatic disease, and treatment history were collected. 33 Each study site performed multiplex genotyping for 10 predefined mutations using any of the following methods: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI; Sequenom Inc, Sand Diego, California), multiplexed single-nucleotide extension sequencing (SNaPshot; Applied Biosystems, Foster City, California), or Sanger sequencing. 34 Every site also performed sizing electrophoresis to detect HER2 insertions and EGFR deletions. The mutation data were entered into the GeneInsight database (GeneInsight, Boston, Massachusetts). Treatment data and vital status were collected annually and recorded in the database until 2012.
Statistical Analysis
In those patients identified as having HER2 mutations, descriptive statistics were used to study demographic and clinical variables. Overall survival was defined as the time from the date of diagnosis of metastatic cancer to the date of death or last follow-up. Survival analysis was performed using the Kaplan-Meier method and the cohorts were compared using log-rank tests at a significance level of .05. All analyses were conducted using SPSS statistical software (version 22.0; IBM Corporation, Armonk, NY).
RESULTS
Of 1007 patients with adequate tumor tissue with which to test for 1 gene, 733 had complete genotyping with all 10 genes. Approximately 64% of the 733 completely tested patients (466 patients) harbored 1 oncogenic driver. A total of 920 patients were tested for HER2 mutations. The prevalence of HER2 mutations was 2.6% (24 patients) (95% confidence interval, 2%-4%). All patients were found to have an exon 20 insertion at codon 775. All but one HER2 mutation was mutually exclusive of other drivers (one patient had concurrent mesenchymalepithelial transition factor [MET] amplification). The baseline demographics are shown in Table 2 . The median age of the patients with HER2 mutations was 62 years (range, 37-73 years). There was a predominance of female patients (58%). Nearly all the patients were neversmokers (71%) or former smokers (25%). Because the LCMC effort focused on patients with metastatic disease, >80% of the patients with HER2 mutations presented with advanced or metastatic disease (TNM Staging for Lung Cancer, 7th edition, stages IIIB-IV). The demographics of the cohort with wild-type HER2 were similar except that the majority of the patients without HER2 mutations were former smokers (60%). Patients with activating HER2 mutations had many different sites of metastatic disease ( Table 3 ). The most frequent site of disease involvement was the lungs, followed by bone, brain, and adrenal metastases. A similar pattern was observed in the patients with wild-type HER2, although there was a higher prevalence of brain metastases in this population (19% vs 12% in the patients with HER2 mutations).
The choice of systemic therapy was varied in the 24 patients harboring HER2 mutations. Of these patients, 12 (50%) received a targeted therapy directed against HER2 (Table 4) . Many of these patients were enrolled in clinical trials with tyrosine kinase inhibitors, including dacomitinib. 25 The patient with the concurrent MET amplification received dacomitinib with crizotinib. Only 3 patients received trastuzumab, either as monotherapy or in combination with lapatinib and bevacizumab. The patients treated with systemic therapy alone received platinum doublets, bevacizumab, pemetrexed, and vinorelbine. A small number of patients received radiation to the thorax (4 patients), brain (2 patients), or bone (1 patient).
The median overall survival of those patients who received HER2-directed therapy was 2.09 years, compared with 1.37 years for patients treated without targeted therapy (P 5 .48) (Figure 1 ). In comparison, the survival of the patients with wild-type HER2 was 2.62 years. At the time of last follow-up, approximately 50% of the patients treated with targeted therapy were alive compared with only 33% of those who received systemic chemotherapy alone. Data were not collected regarding the response rates associated with treatment.
DISCUSSION
Lung adenocarcinomas are a heterogeneous group of tumors and are characterized by a variety of molecular abnormalities. In addition to EGFR and KRAS mutations, each of the other driver events is observed in <5% of patients. Anaplastic lymphoma kinase (ALK), RET, and ROS1 fusion abnormalities are noted in approximately 5%, 1%, and 1% of patients, respectively. 35 These patients are candidates for treatment with crizotinib and other ALK inhibitors. Recently, an exon splicing mutation in the MET gene was found in nearly 4% of patients, causing prolonged stability of the MET protein due to loss of the ubiquitin-binding domain needed for protein degradation. 36 This group appears to benefit from MET inhibitors, as was observed in 3 patients who responded to MET inhibition with crizotinib or capmatinib 36 ; in another recent report, 3 of 8 patients responded to crizotinib or cabozantinib. 37 In larger cohorts of patients with NSCLC, MET exon 14 skip mutations have been reported in 3% of patients and are being investigated as a new target for MET inhibitors. 38, 39 Consequently, the rationale to screen for the less common molecular events beyond EGFR, KRAS, and ALK is growing as additional oncogenic drivers are identified that can be treated effectively with agents targeted against these drivers. HER2 mutations in patients with lung cancer occur in a subset of patients with adenocarcinomas and result in a unique clinical phenotype compared with other oncogenic drivers in lung cancers. The current analysis of HER2 mutations in the LCMC adds to the current understanding of the impact of HER2 mutations in patients with lung cancers.
The incidence of HER2 mutations found in the LCMC (2.6%) is similar to that of previous reports in the literature. In addition, this population exclusively had the YVMA amino acid repeat at codon 775. Although HER2 mutations tend to be mutually exclusive of other oncogenic drivers, we found one patient with a concurrent MET amplification. To the best of our knowledge, the current analysis includes a more robust genetic evaluation of the tumors than any previous report. 30, 31 The Cancer Genome Atlas study of patients with lung adenocarcinoma (230 patients) included 5 patients with HER2 mutations; none had coincident amplification of MET. 40 Unfortunately, data regarding HER2 protein expression by immunohistochemistry and gene amplification by copy number by next-generation sequencing or fluorescence in situ hybridization were not obtained in the LCMC platform.
Unlike EGFR mutations, the prevalence of HER2 mutations appears to be similar between Asian and white patient populations. In common with patients with EGFR-mutant lung cancers, those harboring HER2 mutations tend to be light smokers or never-smokers and are more likely to be women. Patients with tumors with HER2 mutations are younger, with a median age of approximately 60 years.
The current analysis of HER2 mutations in the LCMC demonstrated shorter survival outcomes in these patients compared with individuals whose tumors harbor EGFR mutations and ALK fusions. The median overall survival of the patients with HER2 mutations who received HER2-directed therapies was no different from that of patients who did not (2.09 years vs 1.37 years; P 5 .48) and was similar to that of the patients with wild-type HER2 (2.62 years). In the overall LCMC population, patients who received targeted therapy for a driver mutation achieved a median survival of 3.5 years whereas those not treated with genotype-directed therapy survived an average of 2.4 years. The survival of the patients with HER2 herein is worse but not very different from the median survival reported by Arcila et al (19 months) 30 and Mazieres et al (23 months) 31 in patients with metastatic disease. The outcomes of the patients with HER2 mutations in the LCMC also were similar to the recent report of the European HER2 (EUHER2) cohort, which reported a median survival of 24 months. 41 The median overall survival of patients with HER2 mutations in the French study reported by Barlesi et al was only 11.5 months; however, their study included patients with a performance status of 2, which would explain the inferior survival outcomes. 32 This suggests that exon 20 mutations in HER2 lead to an aggressive phenotype and may be a marker of poor prognosis. Similarly, HER2 amplification in patients with breast cancer and gastric cancer has been associated with a shorter survival. 5, 6, 11 There is a great need to improve outcomes for patients with HER2-mutant lung cancers. There have been case reports regarding the benefits of trastuzumab with taxanes, pan-HER inhibitors such as dacomitinib, and a combination of lapatinib and bevacizumab in patients with HER2 mutations. [42] [43] [44] [45] In the analysis of the European cohort with HER2 mutations, some patients were treated successfully with trastuzumab plus chemotherapy combinations and afatinib. 31 More recently, a phase 2 study of dacomitinib that included 26 patients with HER2 mutations achieved a response rate of 12% (95% confidence interval, 2%-30%). 25 In a phase 1 study of neratinib, an irreversible pan-HER inhibitor, administered in combination with temsirolimus, 2 patients with HER2-mutant lung cancer responded. 46 This formed the basis for a phase 2 randomized study of neratinib with or with temsirolimus. Of the 27 patients treated, the overall response rate was 21% with combination therapy whereas no responses were noted with the use of neratinib alone. 26 There currently are several ongoing clinical trials investigating HER2-targeted therapies in patients with HER2-mutated and amplified NSCLC. These include trastuzumab emtansine (ClinicalTrials.gov identifiers NCT02675829 and NCT0231448), afatinib (ClinicalTrials.gov identifiers NCT02183883, NCT02795156, and NCT02597946), and lapatinib (ClinicalTrials.gov identifier NCT01306045). Newer agents targeting the HER2 pathway, including pyrotinib (an oral tyrosine kinase dual inhibitor of HER2 and HER2 [ClinicalTrials. gov identifier NCT02834936]), poziotinib (a pan-HER inhibitor [ClinicalTrials.gov identifier NCT02979821]), and bispecific monoclonal antibodies against HER2 such as MCLA-128 (ClinicalTrials.gov identifier NCT02912949) and ZW25 (ClinicalTrials.gov identifier NCT02892123), are in the early phases of clinical development. Strategies using the immune system, such as chimeric antigen receptor T cells (ClinicalTrials.gov identifier NCT02713984) and vaccines targeting HER2 (ClinicalTrials.gov identifier NCT02713984), also are being investigated. To the best of our knowledge, the current study is the first to compare overall survival outcomes for patients treated with HER2-directed therapy compared with those who did not receive targeted therapy. Although there was no significant difference in survival observed between patients with HER2 mutations who received targeted therapy and those who did not, this was a small sample size and included different HER2 therapies. We believe the further development of therapies that more effectively target HER2 mutations still has the potential to improve outcomes for this group of patients with a poor prognosis.
HER2 mutations are present in a subset of patients with lung adenocarcinoma. Patients with activating exon 20 HER2 mutations appear to have worse survival outcomes compared with other patients with lung adenocarcinomas with oncogenic drivers. Further research into new targeted therapies targeting HER2 in lung cancers has the potential to improve outcomes in this molecular subset of patients.
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